Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression.
Morgan
Susan J
SJ
Seymour
John F
JF
Prince
H Miles
HM
Westerman
David A
DA
Wolf
Max M
MM
D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D045744:Cell Line, Tumor; D002886:Chromosomes, Human, Pair 17; D004167:Diphtheria Toxin / Q000737:chemistry* / Q000627:therapeutic use; D005260:Female; D017353:Gene Deletion; D006801:Humans; D007376:Interleukin-2 / Q000737:chemistry* / Q000627:therapeutic use; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis; D011993:Recombinant Fusion Proteins / Q000737:chemistry* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004167:Diphtheria Toxin; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox